Lucia Tweezers - Lavipharm VP Board

All Insiders . Greece . 
Stock . Lavipharm SA . Stakeholders . Insider . Lucia Tweezers
LAVI Stock  EUR 0.83  0.02  2.35%   

Insider

Lucia Tweezers is VP Board of Lavipharm SA
Phone30 210 66 91 000
Webhttps://www.lavipharm.gr

Lavipharm Management Efficiency

The company has return on total asset (ROA) of 0.0403 % which means that it generated a profit of $0.0403 on every $100 spent on assets. This is way below average. Lavipharm's management efficiency ratios could be used to measure how well Lavipharm manages its routine affairs as well as how well it operates its assets and liabilities.
Lavipharm SA has accumulated 40.54 M in total debt. Lavipharm SA has a current ratio of 1.26, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Lavipharm until it has trouble settling it off, either with new capital or with free cash flow. So, Lavipharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lavipharm SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lavipharm to invest in growth at high rates of return. When we think about Lavipharm's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Gregory PapagrigorisNational Bank of
N/A
Kaiti IoanniElton International Trading
56
Georgios TriantafillakisNational Bank of
66
Stavroula MarkouliMarfin Investment Group
N/A
Stelios VasiliouElton International Trading
67
PanagiotisIoannis DasmanoglouNational Bank of
60
Elias GeorgantasIntertech SA Inter
N/A
Nektarios DivarisNational Bank of
N/A
Ekaterini TsouraProfile Systems Software
49
Christos ChristodoulouNational Bank of
47
Antonis YassarisElton International Trading
N/A
Charalampos StasinopoulosProfile Systems Software
61
Theodora TsotakiIntertech SA Inter
57
Vasilis KaramouzisNational Bank of
46
Chloe LaskaridisLampsa Hellenic Hotels
N/A
Frosso MichalatouElton International Trading
N/A
Anastasios HomenidisLampsa Hellenic Hotels
69
Nestor PapathanasiouElton International Trading
82
Christina TheofilidiNational Bank of
56
Evangelos AngelidisProfile Systems Software
52
Dimitrios GiotopoulosElton International Trading
54
Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece. LAVIPHARM operates under Drug Manufacturers - Major classification in Greece and is traded on Athens Stock Exchange. Lavipharm SA (LAVI) is traded on Athens Exchange in Greece and employs 5 people.

Management Performance

Return On Asset0.0403

Lavipharm SA Leadership Team

Elected by the shareholders, the Lavipharm's board of directors comprises two types of representatives: Lavipharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lavipharm. The board's role is to monitor Lavipharm's management team and ensure that shareholders' interests are well served. Lavipharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lavipharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
Katerina Fragioudakis, Head Chairman
Vassilis Baloumis, Group CFO
Panagiotis Giannouleas, COO Mang
Spyridon Fotinos, Chief Officer
Liana Dimitrakopoulou, Investor Officer
Lucia Tweezers, VP Board
Panagiotis Pavlou, Group Director
Eleana Nikolopoulou, Group Sec
Telemaque Lavidas, Ex Director

Lavipharm Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lavipharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset0.0403
Profit Margin0.02 %
Operating Margin0.08 %
Current Valuation59.98 M
Shares Outstanding18.29 M
Shares Owned By Insiders67.47 %
Price To Earning12.42 X
Price To Sales0.17 X
Revenue41.37 M
Gross Profit15.89 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Lavipharm Stock Analysis

When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY